6 out of 7 patients (85.7%) showed clinical remission (PGA score ≤ 1) and closure of target ulcer in the highest dose cohort Treatment was well tolerated; no dose-related adverse events observed Final ...
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative ...
Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the first 5 patients previously announced in Q1 2020 JENA, Germany, April 15, 2021 ...
JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
Darin hatten 13 Patienten mit Pyoderma gangraenosum (Dermatitis ulcerosa) randomisiert und doppelblind eine einmalige Infusion mit 5 mg/kg des TNF-alpha-Blockers Infliximab (Remicade®) erhalten. 17 ...
Ein 72-jähriger Patient stellte sich in unserer Klinik mit seit zehn Jahren rezidivierenden Ulzerationen am rechten Gaumenbogen vor. In der Vergangenheit war eine Exzision der Läsion erfolgt, die ein ...
JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
Target enrollment of 18 patients reached across three different dose groups Interim results will be available by the end of 2021 with final results expected in 2022 Initial positive data from the ...
Four out of 10 evaluable patients showed clinical response (PGA score ≤ 3), three of whom achieved complete closure of target lesion Treatment was well tolerated; no adverse events associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback